Genexine, Inc. (KOSDAQ: A095700)
Health Care · Biotechnology · KR
₩2,905.00
+4.87% today · -52.8% 1Y
Genexine, Inc. (KOSDAQ: A095700) operates in the Biotechnology industry within the Health Care sector. The company is valued at $98.27M.
Over the last twelve months the share price has lost 52.8%, trading between 2.14K and 7.49K.
Tweenvest scores Genexine, Inc. across four factors: quality 45/100, value 44/100, growth 0/100. Its strongest factor is quality.
A095700 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $98.27M
- Revenue (TTM)
- $4.32M
- P/E
- —
- EPS
- -1,320.62
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- ₩7,490.00
- 52-week low
- ₩2,140.00
- Avg volume (3M)
- —
- Shares outstanding
- 45.48M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Anixa Biosciences, Inc.NasdaqCM: ANIX | $100.82M | $2.67 | -7.93% |
| Faron Pharmaceuticals OyAIM: FARN | $99.76M | £0.37 | +5.19% |
| Humacyte, Inc.NasdaqGS: HUMA | $99.70M | $0.36 | +0.33% |
| HST Global, Inc.OTCPK: HSTC | $99.00M | $0.70 | +600.00% |
| Novogenia AGMUN: 7V0 | $98.11M | €7.20 | — |
| OnKure Therapeutics, Inc.NasdaqGM: OKUR | $97.60M | $2.25 | -6.64% |
| CanBas Co., Ltd.TSE: 4575 | $96.69M | ¥801.00 | +8.39% |
| Black Diamond Therapeutics, Inc.NasdaqGS: BDTX | $96.52M | $1.67 | -0.60% |
Figures last refreshed Oct 11, 2026.